文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

供者来源CD7 CAR T细胞治疗儿童及成人复发/难治性T细胞急性淋巴细胞白血病/淋巴瘤的2期试验

Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial.
PubMed 文献 · Blood · 2025-01-01

这项2期试验评估了来自既往移植供者或新配型HLA相合供者的CD7 CAR T细胞,用于复发/难治性T-ALL/LBL。因科室关闭提前终止,计划70例中55例接受治疗;3个月内89%达最佳总体疗效为部分缓解或更好,中位随访26.3个月,中位无事件生存5.0个月,中位总生存8.5个月;30天后非复发死亡11例,占治疗患者20%。

要点

  • 55例接受供者来源CD7 CAR T细胞治疗,3个月内89%达部分缓解或更好。
  • 中位随访26.3个月,中位无事件生存5.0个月,中位总生存8.5个月。
  • 30天内无死亡;30天后非复发死亡11例,占治疗患者20%。

核心结论

  • 供者来源CD7 CAR T细胞虽能有效诱导缓解,但30天后的缓解期死亡是值得关注的问题。

研究设计与样本

  • 这项2期试验评估来自既往移植供者或新配型HLA相合供者的CD7 CAR T细胞,治疗复发/难治性T-ALL/LBL。
  • 因科室关闭提前终止,计划入组70例,实际接受治疗55例。

主要发现

  • 3个月内89%的治疗患者达最佳总体疗效为部分缓解或更好。
  • 19例接受了干细胞移植,中位时间为1.3个月(范围1.0-10.6)。
  • 中位随访26.3个月,中位无事件生存5.0个月(95%CI 4.1-8.4),中位总生存8.5个月(95%CI 6.1-15.6)。
  • 30天内无死亡;细胞因子释放综合征1-2级87%、3级11%,神经毒性1级9%。
  • 移植物抗宿主病1-2级38%、3级2%;1-2级感染29%;血细胞减少2级4%、3-4级96%。

关键数值与推荐

  • 30天后3-5级不良事件:血细胞减少3级24%、4级67%;感染3级9%、4级5%、5级9%;移植物抗宿主病3级4%、5级4%;血栓性微血管病5级4%;肝衰竭5级2%。
  • 30天后非复发死亡11例,占治疗患者20%,占未接受巩固移植的缓解者35%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因科室关闭提前终止,计划70例中仅55例接受治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 2 trial assessed CD7 chimeric antigen receptor (CAR) T cells derived from previous transplant or newly HLA-matched donors for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Early termination from departmental closure yielded 55 treated patients out of 70 planned. Within 3 months, 89% of treated patients achieved best overall response of partial remission or better. A total of 19 received stem cell transplantation at a median of 1.3 (range, 1.0-10.6) months. After a 26.3-month median follow-up, median event-free survival was 5.0 months (95% confidence interval [4.1-8.4]), with median 8.5-month overall survival (95% confidence interval [6.1-15.6]). No deaths occurred within 30 days; adverse events included cytokine release syndrome in 87% at grades 1 to 2 and 11% at grade 3 and neurotoxicity in 9% at grade 1. In addition, graft-versus-host disease was in 38% at grades 1 to 2 and 2% at grade 3. Grades 1 and 2 infections occurred in 29%. Cytopenias occurred in 4% at grade 2 and 96% at grades 3 and 4. After 30 days, grades 3 to 5 adverse events included cytopenias (grade 3 in 24%; grade 4 in 67%), infections (grade 3 in 9%; grade 4 in 5%; grade 5 in 9%), graft-versus-host disease (grade 3 in 4%; grade 5 in 4%), thrombotic microangiopathy (grade 5 in 4%), and hepatic failure (grade 5 in 2%). Furthermore, 11 encountered nonrelapse mortality after 30 days, representing 20% of treated patients and 35% of responders without consolidatory transplantation. Although effective at inducing remission, death in remission beyond 30 days is a concern. This trial was registered at www.clinicaltrials.gov as #NCT04689659.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pan J, Zhao L, Zhang Y, et al. Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial. Blood. 2025. PMID: 40712157. doi:10.1182/blood.2025029299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。